Apimeds Pharmaceuticals US (APUS) Liabilities and Shareholders Equity (2023 - 2025)

Apimeds Pharmaceuticals US's Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $164.2 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 1257338.43% year-over-year to $164.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $184.2 million (up 1410946.62% YoY) and the FY2025 annual result came in at $164.2 million, up 1257338.43% from the prior year.
• Liabilities and Shareholders Equity was $164.2 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $9.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $164.2 million in Q4 2025 and bottomed at $13057.0 in Q4 2024.
• A 3-year average of $30.8 million and a median of $4.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity plunged 96.91% — and 2025, when it surged 1257338.43%.
• Apimeds Pharmaceuticals US's Liabilities and Shareholders Equity stood at $422076.0 in 2023, then plunged by 96.91% to $13057.0 in 2024, then jumped by 1257338.43% to $164.2 million in 2025.
• Business Quant data shows APUS's Liabilities and Shareholders Equity at $164.2 million in Q4 2025, $9.3 million in Q3 2025, and $10.5 million in Q2 2025.